Shares of GlaxoSmithKline plc (NYSE:GSK) have received an average rating of “Hold” from the seventeen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $39.50.
A number of research analysts recently commented on GSK shares. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, January 2nd. UBS raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $35.04 to $35.85 in a report on Monday, November 27th. Barclays raised GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 16th. Argus lowered their price target on GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday, November 30th. Finally, Cowen set a $38.00 price target on GlaxoSmithKline and gave the stock a “hold” rating in a report on Monday, December 11th.
GSK stock traded down $0.38 during midday trading on Wednesday, reaching $37.04. The company had a trading volume of 1,583,259 shares, compared to its average volume of 4,112,126. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. GlaxoSmithKline has a one year low of $34.52 and a one year high of $44.53. The stock has a market cap of $92,780.42, a PE ratio of 46.89, a PEG ratio of 2.08 and a beta of 0.95.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be paid a $0.633 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a yield of 6.84%. GlaxoSmithKline’s payout ratio is presently 320.26%.
A number of large investors have recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. increased its stake in GlaxoSmithKline by 5.5% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 107,873 shares of the pharmaceutical company’s stock worth $3,826,000 after acquiring an additional 5,582 shares during the last quarter. OLD Republic International Corp increased its stake in GlaxoSmithKline by 22.1% in the 4th quarter. OLD Republic International Corp now owns 1,538,500 shares of the pharmaceutical company’s stock worth $54,571,000 after acquiring an additional 278,000 shares during the last quarter. Letko Brosseau & Associates Inc. increased its position in shares of GlaxoSmithKline by 3.0% during the 4th quarter. Letko Brosseau & Associates Inc. now owns 1,027,688 shares of the pharmaceutical company’s stock valued at $36,452,000 after purchasing an additional 30,000 shares during the last quarter. Delek Group Ltd. bought a new position in shares of GlaxoSmithKline during the 4th quarter valued at approximately $1,229,000. Finally, Sawtooth Solutions LLC increased its position in shares of GlaxoSmithKline by 316.0% during the 4th quarter. Sawtooth Solutions LLC now owns 24,054 shares of the pharmaceutical company’s stock valued at $853,000 after purchasing an additional 18,272 shares during the last quarter. 10.96% of the stock is currently owned by institutional investors and hedge funds.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.